2020
Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer
Alvero AB, Hanlon D, Pitruzzello M, Filler R, Robinson E, Sobolev O, Tedja R, Ventura A, Bosenberg M, Han P, Edelson RL, Mor G. Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer. OncoImmunology 2020, 9: 1758869. PMID: 32566387, PMCID: PMC7302442, DOI: 10.1080/2162402x.2020.1758869.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian cancerSyngeneic mouse modelOvarian cancerRecurrent diseaseMouse modelRecurrent high-grade serous ovarian cancerEffective anti-tumor immune responseDendritic cell vaccination strategiesHuman cutaneous T cell lymphomaAnti-tumor immune responseMyeloid-derived suppressive cellsCutaneous T-cell lymphomaIntra-peritoneal tumorsWhole tumor antigenChemotherapy-resistant diseaseFirst-line standardT-cell lymphomaOvarian cancer accountsSerous ovarian cancerTumor-associated macrophagesImmunotherapeutic interventionsGynecologic malignanciesSuppressive cellsDisease coursePatient survival
2019
Extracorporeal photochemotherapy induces bona fide immunogenic cell death
Tatsuno K, Yamazaki T, Hanlon D, Han P, Robinson E, Sobolev O, Yurter A, Rivera-Molina F, Arshad N, Edelson RL, Galluzzi L. Extracorporeal photochemotherapy induces bona fide immunogenic cell death. Cell Death & Disease 2019, 10: 578. PMID: 31371700, PMCID: PMC6675789, DOI: 10.1038/s41419-019-1819-3.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine TriphosphateAnimalsAntigens, NeoplasmApoptosisCD8-Positive T-LymphocytesCell DifferentiationCell Line, TumorCell SurvivalDendritic CellsHMGB1 ProteinHumansImmunogenic Cell DeathLeukocytesLymphoma, T-Cell, CutaneousMethoxsalenMiceMonocytesPhotopheresisPhotosensitizing AgentsReceptor, Interferon alpha-betaUltraviolet RaysConceptsHigh mobility group box 1Tumor-associated antigensCutaneous T-cell lymphomaWhite blood cellsDendritic cellsImmunostimulatory signalsI interferonBona fide immunogenic cell deathMobility group box 1Such dendritic cellsSyngeneic immunocompetent miceCancer cellsT-cell lymphomaType I IFN receptorGroup box 1Immunogenic cell deathI IFN receptorATP-degrading enzymeSecretion of ATPMelanoma cell viabilityCognate immunityUVA irradiationAnticancer immunityImmunocompetent miceCalreticulin exposureNovel Protocol for Generating Physiologic Immunogenic Dendritic Cells.
Ventura A, Vassall A, Yurter A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL. Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells. Journal Of Visualized Experiments 2019 PMID: 31157760, DOI: 10.3791/59370.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaDendritic cellsCellular vaccinesClinical efficacyAnti-tumor T cell immunityVivo anti-tumor responsesMonocyte-derived dendritic cellsTumor cellsSyngeneic mouse tumor modelsImmunogenic dendritic cellsAnti-cancer immunityT cell immunityAnti-tumor responseHuman dendritic cellsT-cell lymphomaAnti-tumor effectsKey mechanistic driversApoptotic tumor cellsMouse tumor modelsCell immunitySafety profileCancer immunotherapyCell lymphomaMouse modelBlood samples
2016
Quantifying in vivo murine antigen-specific T cell responses without requirement for prior knowledge of antigen identity
Kibbi N, Hong E, Ezaldein H, Hanlon D, Fahmy T, Edelson R. Quantifying in vivo murine antigen-specific T cell responses without requirement for prior knowledge of antigen identity. Transfusion And Apheresis Science 2016, 56: 179-189. PMID: 28007431, DOI: 10.1016/j.transci.2016.11.004.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaExtracorporeal photochemotherapyCalcium fluxT cellsAntigen-specific T cell responsesMalignant cellsPatient-specific tumor antigensOVA-specific T cellsAntigen-specific T cellsAntigen-specific T cell activationControl recipient micePeptide-loaded DCImmune-based therapiesAnti-tumor responseT cell responsesAnti-cancer immunotherapyT-cell lymphomaT cell engagementT cell activationT cell receptor engagementPatient-specific responsesAdoptive transferClinical responseLymph nodesPeripheral blood
2002
Transimmunization, a novel approach for tumor immunotherapy
Berger CL, Hanlon D, Kanada D, Girardi M, Edelson RL. Transimmunization, a novel approach for tumor immunotherapy. Transfusion And Apheresis Science 2002, 26: 205-216. PMID: 12126207, DOI: 10.1016/s1473-0502(02)00014-9.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaImmune responseTumor antigensPotent antigen presenting cellsAnti-tumor immune responseExtracorporeal photopheresis (ECP) treatmentDendritic cell immunotherapyT-cell lymphomaAntigen presenting cellsPeripheral blood monocytesApoptotic tumor cellsApoptotic CTCL cellsPhotopheresis treatmentRejection episodesHost diseaseOvernight incubation periodTumor epitopesImmature DCsCell immunotherapyTumor immunotherapyAutoimmune diseasesDC differentiationInflammatory cytokinesPresenting cellsCell lymphomaEfficient Tumor Antigen Loading of Dendritic Antigen Presenting Cells by Transimmunization
Girardi M, Berger C, Hanlon D, Edelson RL. Efficient Tumor Antigen Loading of Dendritic Antigen Presenting Cells by Transimmunization. Technology In Cancer Research & Treatment 2002, 1: 65-69. PMID: 12614179, DOI: 10.1177/153303460200100109.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMalignant T cellsT cellsTumor antigen loadingAnti-tumor immunityManagement of patientsT-cell lymphomaAntigen presenting cellsDendritic cell differentiationDendritic cellsSelective immunotherapyPresenting cellsOnly FDATumor antigensCell lymphomaAntigen loadingTumor cellsKey cellular eventsTransimmunizationImmunotherapyPatientsCancerRecent findingsEfficient phagocytosisCells